Drucker commented: GLP1 [drugs] have given us so many wonderful results, but tackling these very challenging brain disorders has been disappointing There was a hope that we would see some benefit, and we didnt. From the Alzheimers Drug Discovery Foundation (ADDF), Howard Fillit, MD, emphasized that even negative trials move the field forward, pointing to the need to target the broader pathobiology of Alzheimers and to consider preventive or combination approaches informed by biomarker profiles
The immunosuppressive microenvironment in GBM restricts the infiltration, activation, and function of immune cells, thereby limiting the efficacy of immunotherapy
The FDA approved setmelanotide in November 2020 for the treatment of obese patients with deficiencies in POMC, PCSK1, or LEPR
Depression, anxiety, trauma, and binge eating each predict weight gain over time, while clinical obesity is associated with elevated rates of mood disorders and disordered eating
Mechanical allodynia (dynamic) Movement across the skin surface triggers pain